Shots:

• Boston will lead the development of selected programs through PoC. GSK gets an option to reacquire each program under pre-agreed terms for development and WW commercialization- after completion of POC studies
• If GSK exercises its repurchase option- Boston to receive a one-time payment and milestones along with royalties. If GSK selects not to reacquire a program- it will be eligible to receive milestones and royalties- meanwhile Boston will continue the development & commercialization of the programs
• The two programs include GSK3903371 and GSK3502421. The agreement follows companies’2018 collaboration for the acquisition of GSK’s 5 programs

 ­ Ref: Businesswire | Image: GSK